U.S. markets closed
  • S&P 500

    3,629.65
    -5.76 (-0.16%)
     
  • Dow 30

    29,872.47
    -173.77 (-0.58%)
     
  • Nasdaq

    12,094.40
    +57.62 (+0.48%)
     
  • Russell 2000

    1,845.02
    -8.51 (-0.46%)
     
  • Crude Oil

    45.81
    +0.10 (+0.22%)
     
  • Gold

    1,805.70
    +0.20 (+0.01%)
     
  • Silver

    23.39
    +0.03 (+0.12%)
     
  • EUR/USD

    1.1920
    +0.0024 (+0.20%)
     
  • 10-Yr Bond

    0.8780
    -0.0040 (-0.45%)
     
  • GBP/USD

    1.3384
    +0.0025 (+0.19%)
     
  • USD/JPY

    104.3970
    -0.0830 (-0.08%)
     
  • BTC-USD

    18,795.69
    -245.14 (-1.29%)
     
  • CMC Crypto 200

    368.46
    -2.05 (-0.55%)
     
  • FTSE 100

    6,391.09
    -41.08 (-0.64%)
     
  • Nikkei 225

    26,296.86
    +131.27 (+0.50%)
     

Autolus Therapeutics: Q1 Earnings Insights

Benzinga Insights
·1 min read

Shares of Autolus Therapeutics (NASDAQ:AUTL) were unchanged at $10.28 after the company reported Q1 results.

Quarterly Results

Earnings per share rose 13.04% year over year to ($0.60), which beat the estimate of ($0.74).

Revenue of $338,000 lower by 82.79% year over year, which missed the estimate of $600,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

Autolus Therapeutics hasn't issued any revenue guidance for the time being.

Conference Call Details

Date: May 07, 2020

View more earnings on AUTL

Time: 09:05 PM ET

Webcast URL: https://edge.media-server.com/mmc/p/ymhc6n4q

Price Action

Company's 52-week high was at $25.90

Company's 52-week low was at $3.00

Price action over last quarter: Up 10.66%

Company Description

Autolus Therapeutics PLC is a biopharmaceutical company. It is engaged in the development of next-generation programmed T cell therapies for the treatment of cancer. The company's pipeline includes AUTO1, AUTO2, AUTO3, AUTO4, and others.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.